Literature DB >> 29507565

High-frequency ultrasonography (HFUS) as a useful tool in differentiating between plaque morphea and extragenital lichen sclerosus lesions.

Rafał Białynicki-Birula1, Radomir Reszke1, Jacek C Szepietowski1.   

Abstract

INTRODUCTION: Morphea and lichen sclerosus (LS) are chronic inflammatory diseases that may pose a diagnostic challenge for a physician. High-frequency ultrasonography (HFUS) is a versatile diagnostic method utilized in dermatologic practice, allowing monitoring the course of the disease, treatment response and differentiation between certain skin disorders. AIM: To prove the usefulness of HFUS in differentiating between plaque morphea and extragenital LS lesions.
MATERIAL AND METHODS: We examined 16 patients with plaque morphea and 4 patients with extragenital LS using 20 MHz taberna pro medicumTM (Germany) device.
RESULTS: Investigations revealed hyperechogenic entrance echo in both morphea and LS lesions, whereas a distinct polycyclic surface of the entrance echo was detected exclusively in LS.
CONCLUSIONS: High-frequency ultrasonography is a current diagnostic modality that may prove useful in differentiating between morphea and LS lesions.

Entities:  

Keywords:  differentiation; extragenital lichen sclerosus; high-frequency ultrasonography; plaque morphea

Year:  2017        PMID: 29507565      PMCID: PMC5831286          DOI: 10.5114/ada.2017.71118

Source DB:  PubMed          Journal:  Postepy Dermatol Alergol        ISSN: 1642-395X            Impact factor:   1.837


Introduction

Morphea (localized scleroderma) is a rare, chronic inflammatory disease of the skin and subcutaneous tissues that progresses to sclerosis. Typical plaque lesions are oval or round and indurated. The inflammatory stage (Figure 1) is characterised by an erythematous halo (lilac ring) [1]. The sclerotic stage (Figure 2) presents with an ivory coloured centre of the lesion. After months to years the skin becomes atrophic and soft, with areas of hypo- or hyperpigmentation (Figure 3). Involvement of deeper structures (fascia, muscles, bones, nerves) may result in disability.
Figure 1

Inflammatory stage of morphea. Erythematous halo is prominent (“lilac ring”)

Figure 2

Sclerotic stage of morphea. Whitish plaques are firm upon palpation

Figure 3

Atrophic stage of morphea. The skin is thin, hypoand hyperpigmentation areas are also visible

Inflammatory stage of morphea. Erythematous halo is prominent (“lilac ring”) Sclerotic stage of morphea. Whitish plaques are firm upon palpation Atrophic stage of morphea. The skin is thin, hypoand hyperpigmentation areas are also visible Lichen sclerosus (LS) is an inflammatory disease as well, affecting superficial dermis or submucosa, leading to hypopigmentation, induration and atrophy. Anogenital lesions are typical, whereas extragenital localization is less frequent, usually including the upper trunk, axillae, buttocks and lateral thighs [2]. The lesions appear as porcelain-white plaques, occasionally presenting follicular dells and ecchymoses. Pruritus, often of severe intensity, may accompany the lesions. Morphea and LS lesions are typically distinguishable from each other basing on clinical and histological examination although occasionally diagnostic difficulties may occur [3]. Both disorders may coexist in an affected individual. Up to 38% of patients diagnosed with morphea suffer from genital LS as well [4], whereas extragenital LS was present in approximately 1.7% of patients with morphea [5]. The association between morphea and LS remains controversial. Peterson et al. [1] defined LS as a subtype of plaque morphea. Uitto et al. [3] observed clinical and histologic features of LS and morphea in the same lesions in 7 of 10 evaluated patients concluding that clinical spectrum may reflect similar etiologic events or closely related pathologic processes. Although ethiopathogenesis of these two entities is not completely understood, autoimmune processes, Borrelia burgdorferi infection or previous trauma have been proposed as common causative factors [2, 6]. Other investigators also reported coexistence of extragenital LS and morphea [7-10]. On the other hand, Patterson and Ackermann [11] deemed LS and morphea as separate clinical entities due to the observation that deeper structures (reticular dermis, subcutaneous tissue) were affected exclusively in morphea. Ensuing studies provided additional data concerning differentiation between LS and morphea [12-16]. Ultrasonography is a versatile diagnostic imaging technique aiding diagnosis in numerous medical specialties. As to dermatology, frequencies of 7.5–15 MHz are used in evaluation of lymph nodes and subcutaneous lesions. 20 MHz and higher frequencies (high-frequency ultrasonography – HFUS) provide physicians with an opportunity to visualize upper layers of the skin in better resolution [17]. High-frequency ultrasonography has proven useful in real time visualization of healthy and lesional skin areas without performing the biopsy. The method is rapid, non-invasive and safe but requires special training of the physician. High-frequency ultrasonography may be utilized in evaluating the progress of several skin disorders and their response to treatment [18, 19]. Additionally, sonographic imaging may aid differential diagnosis in certain dermatoses.

Aim

Our study attempted to establish usefulness of HFUS in differentiating between plaque morphea and extragenital LS lesions.

Material and methods

We examined 16 consecutive patients admitted to our Department of Dermatology due to plaque morphea (16 females; mean age: 35.9 ±14.3 years) and 4 consecutive patients presenting extragenital LS (4 females; mean age: 55 ±9 years). Each diagnosis had been previously confirmed by histological examination of skin biopsy specimens. Ultrasonographic imaging was performed utilizing 20 MHz taberna pro medicum TM (Germany) device. The data were collected and saved using DUB micro ® tpm and DUB 6100 v 1.0 software. The parameters of axial and lateral resolution were approximately 80 μm and 200 μm, respectively. The length and the depth of investigation reached 12.8 mm and 8 mm, respectively. Measurements and echogenicity of the structures were assessed in both A-mode and B-mode. The densitometry value was defined as the mean height of reflection amplitude, measured in a standardized colour scale of 255 amplitude levels. In B-mode images dark colours were associated with hypoechogenic structures, bright colours with hyperechogenic structures. Each subject was evaluated in lesional and corresponding contralateral healthy skin areas as well, providing a point of reference. The study was approved by the local ethics committee.

Results

Healthy areas of the skin examined with HFUS revealed a hyperechogenic entrance echo, a normoechogenic area below (representing dermis) and a hypoechogenic or anechogenic zone associated with subcutaneous tissues (Figure 4). The border between dermis and subcutaneous tissues was linear. Linear hyperechogenic structures below represented muscle fascia.
Figure 4

Typical HFUS image of healthy skin regions. On the left side of the figure, hyperechogenic entrance echo is present, followed by a normoechogenic area representing dermis (1670 μm of thickness) and a hypoechogenic or anechogenic zone associated with subcutaneous tissues

Typical HFUS image of healthy skin regions. On the left side of the figure, hyperechogenic entrance echo is present, followed by a normoechogenic area representing dermis (1670 μm of thickness) and a hypoechogenic or anechogenic zone associated with subcutaneous tissues Each patient suffering from plaque morphea (in every stage: inflammatory, sclerotic and atrophic) demonstrated a hyperechogenic entrance echo in HFUS. Examinations revealed a widened, normo- and hypoechogenic areas below in 4 cases. Upon clinical examination, lesions were indurated during palpation. Eleven patients presented a narrow hypoechogenic area depicting the fibrosing process in dermis (Figure 5). Subjects with extragenital LS presented a hyperechogenic entrance echo along with the distinct polycyclic surface. Below, a narrow hypoechogenic area was detected. The dermis area was markedly widened and hypoechogenic as well (Figure 6). Clinical details regarding each patient are summarized in Tables 1 and 2.
Figure 5

High-frequency ultrasonography image of a morphea lesion. Hyperechogenic entrance echo. Thin area of dermis (1200 μm vs. 1450 μm in the clinically unchanged skin)

Figure 6

High-frequency ultrasonography image of an extragenital lichen sclerosus lesion. Widened, hyperechogenic and polycyclic entrance echo

Table 1

Clinical details of patients with plaque morphea

Patient no.AgeLocalizationClinical featuresUltrasonographic examination
124ThighInflammatory stageHyperechogenic entrance echo. Widened area of dermis(1500 μm in the lesional skin vs. 1350 μm in the healthy skin)
227ThighInflammatory stageHyperechogenic entrance echo. Widened area of dermis(1750 vs. 1250 μm)
325ThighAdvanced sclerotic stageHyperechogenic entrance echo. Widened, hypoechogenic area of dermis (2600 vs. 1200 μm)
437ThighSclerotic stageHyperechogenic entrance echo. Thin, hypoechogenic areaof dermis (860 vs. 1500 μm)
536ThighSclerotic stageHyperechogenic entrance echo. Thin, hyperechogenic areaof dermis (850 vs. 1100 μm)
628ThighSclerotic stageHyperechogenic entrance echo. Thin, hyperechogenic areaof dermis (850 vs. 1100 μm)
744ThighAtrophic stageHyperechogenic entrance echo. Thin area of dermis(1250 vs. 1800 μm)
827ArmAtrophic stageHyperechogenic entrance echo. Thin area of dermis(700 vs. 1000 μm)
911ThighAtrophic stageHyperechogenic entrance echo. Thin area of dermis(1200 μm vs. 1450 μm) (Figure 1)
1014ThighAtrophic stageHyperechogenic entrance echo. Thin area of dermis(1200 vs. 1670 μm)
1158ForearmAtrophic stageHyperechogenic entrance echo. Thin area of dermis(580 vs. 800 μm)
1242BackSclerotic stageHyperechogenic entrance echo. Thin, hyperechogenic areaof dermis (1000 vs. 2300 μm)
1356ShoulderDeep morpheaHyperechogenic entrance echo. Hypoechogenic, widened areaof dermis (1570 vs. 1370 μm)
1453ShoulderDeep morpheaHyperechogenic entrance echo. Hypoechogenic, widened areaof dermis (2344 vs. 1534 μm)
1548ShoulderDeep morpheaHyperechogenic entrance echo. Hypoechogenic, widened areaof dermis (3400 vs. 1300 μm)
1644WristDeep morpheaHyperechogenic entrance echo. Hypoechogenic, widened areaof dermis (2300 vs. 1000 μm)
Table 2

Clinical details of patients with extragenital LS

Patient no.AgeLocalizationClinical featuresUltrasonographic examination
150BackElevated plaqueWidened, hyperechogenic and polycyclic entrance echo
254BackElevated plaqueWidened, hyperechogenic and polycyclic entrance echo (Figure 2)
348WristSlightly elevated plaqueHyperechogenic, polycyclic entrance echo was both widened and thin. Anechogenic structures below. Widened dermis area(2100 vs. 1470 μm)
468BackBlister and elevated plaqueHyperechogenic, polycyclic entrance echo. Widened dermis area (3200 vs. 2400 μm)
Clinical details of patients with plaque morphea Clinical details of patients with extragenital LS High-frequency ultrasonography image of a morphea lesion. Hyperechogenic entrance echo. Thin area of dermis (1200 μm vs. 1450 μm in the clinically unchanged skin) High-frequency ultrasonography image of an extragenital lichen sclerosus lesion. Widened, hyperechogenic and polycyclic entrance echo

Discussion

High-frequency ultrasonography is a useful diagnostic modality in dermatology, which complements the diagnosis and monitoring of various disorders. Hoffmann et al. [20] and Kreuter et al. [5] reported HFUS usefulness in monitoring the course and treatment of morphea. Similar conclusions were reached by Szymanska et al. [21] who analysed both morphea and LS lesions. Chen et al. [22] described a case of a 54-year-old woman with an abdominal LS lesion resembling morphea. The HFUS implied the diagnosis of LS, further confirmed by a skin biopsy. However, the authors did not describe new ultrasonographic phenomena supporting the differential diagnosis. To our knowledge, our study is the first to report that hyperechogenic, polycyclic entrance echo is a characteristic ultrasonographic feature of LS. In clinical practice, the differential diagnosis between plaque morphea and extragenital LS lesions may occasionally pose a challenge to a dermatologist. Should doubts concerning the diagnosis arise, histological evaluation of the skin biopsy specimen is the proceeding of choice. Several authors compared histological features of morphea and LS. Rahbari [12] reported decreased or absent elastic fibers in upper dermis of LS subjects as opposed to morphea lesions. The specimens were stained with hematoxylin and eosin as well as Pinkus acid orcein. Nishioka [13] observed that collagen fibers in reticular dermis in morphea and LS are green in polarized microscopy following Picrosirius Red staining. In early stages of LS, collagen fibers in papillary dermis were orange, whereas late-stage lesions appeared green. Differences in colour were are also evident in morphea: collagen fibers just below the epidermis were orange yellow and in the papillary dermis – green. Shono et al. [14] reported different epidermal lectin binding profiles in LS and morphea. Kowalewski et al. [15] applied histochemical staining to basement membrane zone (BMZ) particles of biopsy specimens and performed examinations using laser scanning confocal microscopy. In morphea, the continuity of BMZ was preserved in all layers, whereas in LS, invaginations and holes were detected in lamina lucida and lamina densa. Additionally, early inflammatory stages of morphea compared with inactive stages and LS demonstrated a different vascular network. Unfortunately, the skin biopsy is invasive and ensuing histologic procedures are relatively time consuming. Therefore, new methods of differentiation have also been described. Shim et al. [16] evaluated the use of dermatoscopy which revealed fibrotic beams in morphea and comedo-like openings and whitish patches in LS. These features represented histologic phenomena: sclerosis in morphea, whereas follicular plugging and skin atrophy in LS.

Conclusions

Our preliminary study implies that HFUS may be useful in differentiating between plaque morphea and extragenital LS. Hyperechogenic, polycyclic entrance echo seems to be a characteristic ultrasonographic phenomenon in extragenital LS lesions, although further studies concerning this issue are necessary.

Conflict of interest

The authors declare no conflict of interest.
  19 in total

1.  Diagnostic usefulness of dermatoscopy in differentiating lichen sclerous et atrophicus from morphea.

Authors:  Woo-Haing Shim; Seung-Wook Jwa; Margaret Song; Hoon-Soo Kim; Hyun-Chang Ko; Moon-Bum Kim; Byung-Soo Kim
Journal:  J Am Acad Dermatol       Date:  2012-04       Impact factor: 11.527

2.  British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010.

Authors:  S M Neill; F M Lewis; F M Tatnall; N H Cox
Journal:  Br J Dermatol       Date:  2010-10       Impact factor: 9.302

3.  Histological comparison of morphea and lichen sclerosus et atrophicus.

Authors:  S Nishioka
Journal:  Kurume Med J       Date:  1997

4.  High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: toward a better understanding of the spectrum of morphea.

Authors:  Virginie Lutz; Camille Francès; Didier Bessis; Anne Cosnes; Nicolas Kluger; Julien Godet; Erik Sauleau; Dan Lipsker
Journal:  Arch Dermatol       Date:  2011-10-17

5.  High-frequency ultrasound as a useful device in the preliminary differentiation of lichen sclerosus et atrophicus from morphea.

Authors:  Hsin-Chi Chen; Takafumi Kadono; Yoshihiro Mimura; Hidehisa Saeki; Kunihiko Tamaki
Journal:  J Dermatol       Date:  2004-07       Impact factor: 4.005

6.  Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center.

Authors:  Alexander Kreuter; Jana Wischnewski; Sarah Terras; Peter Altmeyer; Markus Stücker; Thilo Gambichler
Journal:  J Am Acad Dermatol       Date:  2012-04-24       Impact factor: 11.527

7.  Coexistence of lichen sclerosus with morphoea showing bilateral symmetry.

Authors:  D H Kim; K R Lee; T Y Kim; M S Yoon
Journal:  Clin Exp Dermatol       Date:  2009-10       Impact factor: 3.470

8.  Histochemical differentiation of localized morphea-scleroderma and lichen sclerosus et atrophicus.

Authors:  H Rahbari
Journal:  J Cutan Pathol       Date:  1989-12       Impact factor: 1.587

Review 9.  Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis.

Authors:  Nicole Fett; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-02       Impact factor: 11.527

10.  Morphea and lichen sclerosus et atrophicus. Clinical and histopathologic studies in patients with combined features.

Authors:  J Uitto; D J Santa Cruz; E A Bauer; A Z Eisen
Journal:  J Am Acad Dermatol       Date:  1980-09       Impact factor: 11.527

View more
  4 in total

Review 1.  Extragenital lichen sclerosus: a comprehensive review of clinical features and treatment.

Authors:  Aaron Burshtein; Joshua Burshtein; Sergey Rekhtman
Journal:  Arch Dermatol Res       Date:  2022-10-05       Impact factor: 3.033

2.  Assessment of Sclerodermoid Chronic Graft-versus-host Disease with Colour Doppler Ultrasound.

Authors:  Priscila Giavedoni; Carmen Martinez; Sebastian Podlipnik; María Suárez-Lleidó; Ignasi Martí-Martí; Daniel Morgado-Carrasco; Montserrat Rovira; Francesc Fernández-Avilés; Gonzalo Gutiérrez; Laura Rosiñol; Joan Cid; Miquel Lozano; José Manuel Mascaró
Journal:  Acta Derm Venereol       Date:  2021-02-16       Impact factor: 3.875

Review 3.  High-frequency ultrasound in clinical dermatology: a review.

Authors:  Jack Levy; Devon L Barrett; Nile Harris; Jiwoong Jason Jeong; Xiaofeng Yang; Suephy C Chen
Journal:  Ultrasound J       Date:  2021-04-20

4.  Skin and mucous membranes' manifestations of dermatological diseases within the genital area in females.

Authors:  Katarzyna Plagens-Rotman; Renata Przybylska; Zygmunt Adamski; Magdalena Czarnecka-Operacz
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.